In preclinical models, L19-IL2 has been shown to enhance the local and abscopal effects of radiotherapy. The clinical safety of L19-IL2 monotherapy has been established previously. In this study, the safety and tolerability of L19-IL2 following Stereotactic Body Radiotherapy (SBRT) was assessed. ...
有图可知,单独注射L19抗体是肿瘤体积较大,注射含IL2、mTNF、mlL12三种细胞因子的免疫细胞因子是肿瘤体积明显减小。 【详解】 A、抗体由浆细胞分泌,可与相应抗原特异性结合,A正确; B、从图中不能看出单独给小鼠注射L19抗体时对肿瘤生长是否发生抑制,B错误; C、细胞因子具有增强细胞毒性T细胞进行免疫的功能,从而抑制...
向肿瘤5T^fe向递送IL12可以用于提髙细胞因子的治疗指数。 Lexigen的科学家已经描述了细胞因子例如IL2和IL12与免疫i^蛋白的融 合以特异l^Mte向细胞因子[17, 49-51]。然而,作为M明的发明人,我们相 信这样的途4贿局限性。我们意^f'j IgG"细胞因子l^^实际上是多功能蛋白 质,并且因此除了^^结绅细胞因子洽l...
Seven derivatives of F16, F8 and L19 [F16-IL2, F16-131I, F16-124I, F8-IL10, L19-IL2, L19-131I, L19-TNF] are currently being investigated in Phase I and Phase II clinical trials in cancer and in rheumatoid arthritis [1], [14], [19]. Tissue remodeling and angiogenesis (e.g., ...
IL2RB C11orf95 FLJ42709 ATF3 NUDT16 RP11-690I21.2 TFCP2L1 ZNF563 NR2F1-AS1 AC020571.3 LINC00662 ANKRD46 NSUN5P2 UPF3B ZFP36 Degree Low High Advanced specific mRNA Advanced specific lncRNA Common mRNA Common lncRNA Positive correlation Negative correlation Common correlation F 9 6 3 0 ...
Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, et al. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncoimmunology (2018) 7:e1414119. doi: 10.1080/2162402X.2017.1414119...
We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).This investigator-initiated, multicentric, randomised controlled open-label phase II clinical ...
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiother Oncol. 2015;116(3):438-42.Rekers NH, Zegers CM, Yaromina A, Lieuwes NG, Biemans R, Senden-Gijsbers BL, Losen M, Van Limbergen EJ, Germeraad WT, Neri D, et ...
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncoimmunology 2015;4(8): e1021541.Nicolle HRekers, Catharina MLZegers, Wilfred TVGermeraad, LudwigDubois, PhilippeLambin. (2015) Long-lasting antitumor effects provided by radiotherapy combined with the ...
Here, we investigate a combination of two immunocytokines (Bifikafusp alfa (L19IL2) and Onfekafusp alfa (L19TNF)) targeting the extradomain B of fibronectin (EDB) for the treatment of high-risk locally advanced BCC and cSCC. EDB is an oncofetal antigen that is undetectable in virtually ...